Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use ...

Reimagining Alzheimer's care in Canada is not just important for the system—it is imperative for all Canadians. We owe it to those affected to provide the dignity and quality of life they deserve. The ...

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and ...

NewAmsterdam Pharma has said that an oral drug it is developing to lower cholesterol has shown preliminary efficacy as a ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...